ESF0 Stock Chart & Stats
€70.38
-€1.50(-3.02%)
At close: 4:00 PM EST
€70.38
-€1.50(-3.02%)
Day’s Range― - ―
52-Week Range€48.00 - €79.12
Previous CloseN/A
Volume281.00
Average Volume (3M)583.00
Market Cap
€13.62B
Enterprise Value€17.48K
Total Cash (Recent Filing)€618.00M
Total Debt (Recent Filing)€5.47B
Price to Earnings (P/E)25.8
Beta0.78
Next Earnings
Mar 02, 2027EPS Estimate
1.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.00
Shares Outstanding176,000,000
10 Day Avg. Volume676
30 Day Avg. Volume583
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.17
Price to Sales (P/S)1.54
P/FCF Ratio20.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€61.25Price Target Upside-12.97% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)3.97
Revenue Forecast (FY)€7.59B
Bulls Say, Bears Say
Bulls Say
Diversified Global Testing PlatformEurofins serves several regulated end markets through a broad laboratory network and varied testing menu. This diversification can reduce dependence on any single customer group, while regulatory and quality requirements support ongoing demand for analytical services.
Strong 2025 Revenue GrowthThe sharp 2025 revenue expansion indicates stronger business activity and improved scale after a less consistent prior period. If the enlarged revenue base is maintained, it can support operating leverage, broader customer reach, and continued investment across Eurofins’ service network.
Positive Operating Cash GenerationOperating cash flow of about €1.30 billion shows that Eurofins’ laboratory and scientific-services operations generate substantial cash from core activities. This provides an internal funding source for capital investment, debt service, and ongoing development of its testing capabilities.
Bears Say
Materially Higher LeverageThe large increase in debt relative to equity reduces financial flexibility and makes the business more exposed to refinancing and interest costs. If operating performance weakens, the higher leverage could constrain investment capacity and limit management’s ability to absorb pressure.
Weaker Free-cash-flow ConversionAlthough cash generation remains positive, declining free cash flow and lower conversion from earnings indicate that more cash is being absorbed by capital spending or working capital. Persistently weaker conversion would reduce funds available for deleveraging, acquisitions, and shareholder returns.
Margin Deterioration And VolatilityThe long-term decline in net margin and unusually low 2025 gross margin create uncertainty about the durability of earnings quality. Even with strong revenue growth, weaker or volatile margins can limit profit conversion and make future results more sensitive to cost conditions.
Eurofins Scientific News
ESF0 FAQ
What was Eurofins Scientific’s price range in the past 12 months?
Eurofins Scientific lowest stock price was €48.00 and its highest was €79.12 in the past 12 months.
What is Eurofins Scientific’s market cap?
Eurofins Scientific’s market cap is €13.62B.
When is Eurofins Scientific’s upcoming earnings report date?
Eurofins Scientific’s upcoming earnings report date is Mar 02, 2027 which is in 156 days.
How were Eurofins Scientific’s earnings last quarter?
Eurofins Scientific released its earnings results on Jul 23, 2026. The company reported €2.09 earnings per share for the quarter, beating the consensus estimate of €1.91 by €0.18.
Is Eurofins Scientific overvalued?
According to Wall Street analysts Eurofins Scientific’s price is currently Overvalued.
Does Eurofins Scientific pay dividends?
Eurofins Scientific does not currently pay dividends.
What is Eurofins Scientific’s EPS estimate?
Eurofins Scientific’s EPS estimate is 1.62.
How many shares outstanding does Eurofins Scientific have?
Eurofins Scientific has 176,000,000 shares outstanding.
What happened to Eurofins Scientific’s price movement after its last earnings report?
Eurofins Scientific reported an EPS of €2.09 in its last earnings report, beating expectations of €1.91. Following the earnings report the stock price went down -3.971%.
Which hedge fund is a major shareholder of Eurofins Scientific?
Currently, no hedge funds are holding shares in DE:ESF0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Eurofins Scientific
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. It provides services, such as agroscience, including biological assessment, consumer and human, environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, including sustainability, audit, certification, quality inspection, QA-QC programme, and food and dietary supplement labelling services; biopharma, and clinical diagnostics. The company also offers consumer product testing, which include sustainability, testing, certifications and approvals, expert services and regulatory, inspections, audits, consumer research and sensory evaluation, and training courses; cosmetics and personal care; and electrical and electronics laboratories services. In addition, it provides environment testing, including maritime, water, air, soil, building material, pollution, waste, fuel/oil, microplastics, and radioactivity testing; and food and feed testing that include allergen, audit and certification, authenticity, carbohydrates, consulting, dioxins and POPs, food irradiation, GMO, heavy metal, melamine, microbiology, molecular biology, mycotoxin, nutritional analyses, organic contaminants, pesticide, veterinary drug, vitamin, and residual DNA testing. Further, the company provides forensic, genomic, maritime, materials and engineering, REACH, and sensory and consumer services, as well as in vitro diagnostics and PSS insourcing solutions. The company was founded in 1987 and is headquartered in Luxembourg, Luxembourg.
ESF0 Stock 12 Month Forecast
Average Price Target
€61.25
▼(-12.97% Downside)









